Navigation Links
Par Pharmaceutical Companies Reports Third Quarter 2011 Results
Date:11/2/2011

settlements and contingencies

-2,250Non-cash interest expense

-533Abrika earn-out payment

-(3,567)Sum of adjustments, pre-tax

$2,852$1,216Estimated tax on adjustments

551(462)Domestic manufacturing tax benefit

-(2,009)Adjusted Income from Continuing Operations (non-GAAP measure)

$25,458$29,406Amortization Expense

2,5483,079Estimated tax impact

(943)(1,170)Amortization Expense, net of tax

1,6051,909Adjusted Cash basis from Continuing Operations (non-GAAP measure)27,06331,315"Cash EPS" from Continuing Operations (non-GAAP measure)$0.74$0.88Diluted weighted average shares outstanding

36,77435,684Nine Months EndedSeptember 30,September 30,20112010(Loss) Income from Continuing Operations($77,609)$75,122Litigation settlements and contingencies, pre-tax

190,560(1,880)Restructuring costs

27,660-Transaction costs for Edict and Anchen

2,852-Upfront and development milestone payments

-19,000Sale of product rights

-(5,000)Non-cash interest expense

-1,571Abrika earn-out payment

-(3,567)Sum of adjustments, pre-tax

$221,072$10,124Estimated tax on adjustments

(58,397)(3,847)Charge related to valuation of deferred income tax assets

2,391-Resolution of tax contingencies

-(3,657)Domestic manufacturing tax benefit

-(2,009)Adjusted Income from Continuing Operations (non-GAAP measure)

$87,457$75,733Amortization Expense

8,66611,233Estimated tax impact

(3,238)(4,269)Amortization Expense, net of tax

5,4286,964Adjusted Cash basis from Continuing Operations (non-GAAP measure)92,88582,697"Cash EPS" from Continuing Operations (non-GAAP measure)$2.54$2.34Diluted weighted average shares outstanding

36,52535,410
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... SGP ), a leader in hepatitis research, ... III studies of boceprevir, its,investigational oral hepatitis C ... virus (HCV) genotype 1. One study,will be in ... patients,who failed prior treatment (relapsers and nonresponders), an ...
... Laboratories, L.C., a,privately-owned biopharmaceutical company, today announced the ... to evaluate the safety and,efficacy of nitazoxanide in ... with chronic hepatitis C genotype 1 who have ... therapy (peginterferon and,ribavirin). The company expects to announce ...
Cached Medicine Technology:Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 2Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 3Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 4Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 5Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 6Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 7Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 8Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 9Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 10Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3
(Date:4/22/2014)... researchers have characterized a set of clock genes that ... types of species, from flies to humans. Over 15 ... there are more. A team from the Perelman School ... big-data approaches could find them. , To accelerate ... professor of Pharmacology and first author Ron Anafi, MD, ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... pregnancy among women using a newer method of planned ... greater over a 10-year period than using the more ... Yale University and UC Davis has found. , ... , the study found the higher risk of pregnancy ... name Essure. , "This study provides essential information ...
(Date:4/22/2014)... 22, 2014) The International Communication Association will ... Seattle, Washington. The theme of the 2014 conference ... a networked and digital society. , Featuring over ... over 2,200 Communication scholars representing over 40 countries, ... communication conference in the world. This year,s conference ...
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
Breaking Medicine News(10 mins):Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... tools, but ,talking, computer program helped , , FRIDAY, ... the written questions American doctors have them answer ... question the usefulness of these screening tools, new ... year at the 2008 Clinical Congress of the ...
... WASHINGTON, Oct. 17 After a destructive,hurricane season that ... the American Public Health Association (APHA) wants to ensure,that ... storms and any other,potential emergencies you may face. With ... a new campaign aimed at encouraging Americans to,make sure ...
... AUBURN HILLS, Mich., Oct. 17 Chrysler LLC ... companies will bring an,innovative diabetes program to its ... developed with the Henry Ford Health System,and is ... and,care with existing workplace wellness initiatives. All employees ...
... into tobacco dependence published online today (Friday 17 October 2008) ... that recent ex-smokers who find exposure to other people,s cigarette ... those who find it unpleasant. , Led by Dr Hayden ... Unit at Barts and The London School of Medicine and ...
... ShotsTM Brings Public Health Message to Austin,s American,Heart ... Heart disease was the leading,cause of death ... in every,10 deaths. People with heart disease are ... complications from the flu. Therefore, the,U.S. Centers for ...
... break fundraising records for breast ... cancer research, SEATTLE, ... Breast Cancer Awareness month to raise money for breast,cancer research. This is ... to help breast cancer research and who has,not completed their will to ...
Cached Medicine News:Health News:Doctors Often Overestimate Patients' Health Literacy 2Health News:Check Your Emergency Preparedness Kits When You Set Your Clocks, Says American Public Health Association Campaign 2Health News:Chrysler LLC Launches Workplace Diabetes Education Program 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 3Health News:How Can Doing Your Will Online Help Cure Breast Cancer? 2
The Bio-Quant CK-MB test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of,CK-MB in human serum specimens as an aid in the diagnosis of myocar...
... heart, the only therapy solution open to them is ... are not always readily available. For this reason, too ... list for a donor organ. , ,This is where ... a patient. On the one hand, these systems can ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
... The Nichols Advantage® 25-Hydroxyvitamin D Assay ... Advantage® Specialty System. The Nichols Advantage® 25-Hydroxyvitamin ... determination of 25-,hydroxyvitamin D (25-OH-D) and other ... or plasma to be used as an ...
Medicine Products: